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ABSTRACT
Diabetes increases the risk of adverse cardiovascular and renal events. Recently, sodium–glucose co-transporter 2 (SGLT2)
inhibitors have been demonstrated to reduce cardiovascular complications and slow diabetic kidney disease progression in
patients with type 2 diabetes. The glycaemic control exerted by these drugs is not greater than the one achieved with other
classical glucose-lowering medications such as sulphonylureas. For that reason, plausible renoprotective mechanisms
independent from glycaemic control have been proposed such as blood pressure control, body weight loss, intraglomerular
pressure reduction and a decrease in urinary proximal tubular injury biomarkers. Interestingly, the hypothesis that SGLT2
inhibitors have a direct renoprotective effect has been addressed in diabetic and non-diabetic models. In this editorial, we
update the different postulated mechanisms involved in the cardiorenal protection afforded by SGLT2 inhibition in chronic
kidney disease.
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Patients with type 2 diabetes mellitus (T2D) have a well-known
increased risk for premature death and cardiorenal complica-
tions. Approximately 35% of patients with T2D will develop
diabetic kidney disease. Furthermore, recently published epide-
miologic studies demonstrate that diabetic nephropathy contrib-
uted 51% of the increased burden of chronic kidney disease (CKD)
since 1990 [1]. Before 2015, glucose-lowering medications were
shown to only slightly reduce diabetic nephropathy progression
during intensive therapy, and were associated with increased ad-
verse effects, mainly in frail patients. Interestingly, no benefit
was found in macrovascular complications and death from car-
diovascular causes [2–5]. Until 2016, cardiorenal treatment in T2D
has been limited to renin–angiotensin system blockade, either by
angiotensin-converting enzyme inhibitors (ACEi) or by
angiotensin II receptor blockers (ARBs) administration [6, 7]. Of
note, the combination of ACEi and ARBs has not demonstrated
beneficial effects on cardiorenal protection in T2D over each
agent alone [8]. Recently, a new class of anti-diabetic drugs—the
sodium–glucose co-transporter 2 (SGLT2) inhibitors—has been
demonstrated to slow the progression of diabetic kidney disease
and to improve cardiovascular outcomes [9–11].
SGLT2 and, to a lesser extent, SGLT1 are responsible for tu-
bular glucose reabsorption in proximal tubules and, thus, they
contribute importantly to glucose homoeostasis. The use of
SGLT2 inhibitors has proven to be effective in glycaemia control
in diabetic patients. SGLT2 inhibition increases urinary glucose
excretion, decreasing blood glucose levels [12]. Canagliflozin,
dapagliflozin and empagliflozin are the approved SGLT2
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inhibitors in the USA and Europe for treatment of T2D. These
drugs were introduced into clinical practice between 2013 and
2015, after several clinical trials that demonstrated their efficacy
in glucose lowering, and also in weight loss and reduction of
blood pressure [13]. Recent studies demonstrated that SGLT2
inhibitors in combination with renin-angiotensin system (RAS)
blockade may decrease major cardiovascular events, usually
measured as a composite outcome of death from cardiovascular
causes, non-fatal myocardial infarction or non-fatal stroke [14,
15]. The first trial focusing on the evaluation of renal outcomes
in diabetic kidney disease was published in 2016. Wanner et al.
[9] demonstrated that the administration of empagliflozin in
T2D patients at high cardiovascular risk was associated with
slower progression of kidney disease and lower rates of clini-
cally relevant renal events as compared with placebo over a me-
dian follow-up period of 3.1 years [16]. Subsequently, Heerspink
et al. [11] demonstrated that canagliflozin slowed renal disease
progression over >2 years of follow-up in T2D patients indepen-
dently of its glycaemic effects. Recently, dapagliflozin adminis-
tration was associated with robust reductions in hospitalization
for heart failure and progression of renal disease, regardless of
baseline atherosclerotic risk category or history of heart failure
[10]. These promising outcomes have to be confirmed in future
trials with renal progression as the primary endpoint that enrol
(or are currently enrolling) patients with more advanced CKD
such as Canagliflozin and Renal Endpoints in Diabetes with
Established Nephropathy Clinical Evaluation, a study to evalu-
ate the effect of dapagliflozin on renal outcomes and cardiovas-
cular mortality in patients with CKD and the study of heart and
kidney protection with empagliflozin [17]. In the current study,
Satirapoj et al. [18] have shown in a randomized controlled trial
that dapagliflozin treatment decreases urinary kidney injury
molecule 1 (uKIM-1) levels. In concordance, Dekkers et al. [19] in
a post hoc analysis also demonstrated a decrease of uKIM-1 after
dapagliflozin treatment. These results suggest that SGLT2
inhibitors exert renoprotection by different mechanisms such
as restoring tubuloglomerular feedback, thus decreasing hyper-
filtration and albuminuria, and directly decreasing tubular in-
jury, among others in T2D patients [9–11, 16, 18, 19] (Figure 1).
For these reason, currently some clinical trials are ongoing to
assess the effect of SGLT2 inhibition on non-diabetic CKD
patients [20].
The renoprotective effects of SGLT2 have also been
explained by natriuresis resulting from inhibition of sodium
and glucose reabsorption. An increased sodium delivery to the
macula densa activates the tubuloglomerular feedback that
leads to afferent arteriole vasoconstriction and a reduction in
intraglomerular pressure. In fact, SGLT2 inhibitors demon-
strated a similar pattern of change in renal function to that ob-
served with ACEi or ARBs, where a short-term decrease of
glomerular filtration rate is followed by stabilization over time
[12]. This initial reduction is also reversible when the drug is
discontinued. Other plausible mechanisms that have been pro-
posed to contribute to SGLT2 inhibitor renoprotection are lower-
ing of blood pressure, weight loss, amelioration of the volume
overload and glycaemic control itself (Figure 1). However, it is
still not clear whether these drugs also exert direct protective
effects on the kidney. To determine whether SGLT2 inhibitors
have a renoprotective effect independent from glycaemia and
blood pressure control, some clinical trials are ongoing to assess
its effect on non-diabetic CKD patients.
Diabetic mice and rat models seem to respond to SGLT2
inhibitors similarly to humans in terms of glycaemia and body
weight control [21]. In addition, the experimental models of dia-
betic nephropathy also showed the cardiorenal protection phe-
notype [22–25]. In contrast, in non-diabetic CKD experimental
models, the results are unclear. Some studies were not able to
demonstrate that SGLT2 inhibitors prevented kidney damage
[26, 27], whereas others demonstrated clear renoprotective
effects [28–32]. In mice with tubular damage induced by chronic
oxalosis, empagliflozin did not improve renal function or fibro-
sis [26]. In concordance, dapagliflozin did not improve the
FIGURE 1: Suggested mechanisms for cardiorenal protection with SGLT2 inhibition.
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glomerular filtration rate in the subtotal nephrectomy model of
glomerulosclerosis in the rat [27]. However, in a rat model of
kidney damage induced by unilateral ureteral obstruction,
SGLT2 inhibition decreased kidney fibrosis and inflammation
biomarkers, such as transforming growth factor-beta 1 (TGF-b1),
alpha smooth muscle actin (a-SMA) or fibronectin. Moreover,
they exhibited a downregulation of the inflammatory Nuclear
factor kappa B/Toll-like receptor 4 (NF-jB/TLR4) signalling path-
way, as well as a partial recovery of tubular klotho levels sug-
gesting that empagliflozin may have a protective effect against
inflammation and fibrosis [30]. Panchapakesan et al. showed
similar results in cultured proximal tubular cells where empa-
gliflozin attenuated the NF-jB/TLR4 pathway. They also demon-
strated that SLGT2 expression was not only induced by high
glucose levels, but also by the profibrotic factor TGF-b1 [28]. In a
mouse model, luseogliflozin prevented fibrosis after kidney in-
jury induced by ischaemia–reperfusion. Increased expression of
vascular endothelial growth factor A (VEGF-A) in the kidneys of
these animals was also observed. Both the decrease of fibrosis
and the VEGF-A overexpression were suppressed when luseogli-
flozin was associated with sunitinib—a VEGF receptor inhibitor.
These results suggest that the protective effects of luseogliflozin
were in part mediated by the VEGF-A pathway [29]. In a murine
protein-overload proteinuria model, dapagliflozin reduced pro-
teinuria and glomerular damage in a similar way to lisinopril—
an ACEi. In the in vivo model and in cultured cells, bovine serum
albumin upregulated SGLT2 expression in podocytes in an NF-
jB-dependent manner. This induced cytoskeleton changes that
reverted with the administration of dapagliflozin. Interestingly,
SGLT2 inhibition may directly target the podocytes and contrib-
ute to maintain the actin cytoskeleton architecture [31].
Hyperglycaemia-induced senescence and oxidative stress on
the tubular cells have also been related to glucose overload. In a
type 1 diabetic rat model, senescence was mediated by SGLT2
and p-21 [32]. Moreover, in cultured tubular cells, high glucose
concentrations induce an inflammatory and proapoptotic state
mainly caused by oxidative stress that was prevented by tofogli-
flozin [33].
The results obtained in non-diabetic CKD models suggest
that SGLT2 inhibitors could also have a direct beneficial effect
on the kidney, which would be independent of the glycaemic
and blood pressure control (Figure 1). Not all the biological path-
ways involved in the cardiorenal protection exerted by SGLT2
inhibitors have been characterized. In addition to high glucose
levels, several studies have observed SGLT2 upregulation by
profibrotic factors like TGF-b1 and protein overload. These find-
ings may explain the implication of this co-transporter in non-
diabetic kidney disease. Furthermore, SGLT2 blockade interacts
with several pathways and signalling molecules such as NF-jB/
TLR4, VEGF-A or klotho, suggesting that these drugs modulate
inflammatory and fibrotic responses. As not all of the non-
diabetic CKD animal models responded to SGLT2 inhibitors [26,
27], it is possible that the direct effects on the kidney are depen-
dent on the specific CKD experimental model studied.
In conclusion, SGLT2 inhibitors have been shown to reduce
cardiovascular complications and to slow diabetic kidney dis-
ease progression in patients with T2D. Interestingly, this effect
was also associated with decreased urinary proximal tubular in-
jury biomarkers. Beside glycaemic and blood pressure control,
these drugs seem to exert direct renoprotective effects that may
explain the results obtained in non-diabetic models of CKD.
However, more evidence is needed to confirm the results, as
well as to explain how and in which specific non-diabetic kid-
ney diseases they could be effective.
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